Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA

Kathy Holliman  |  Issue: June 2012  |  June 10, 2012

Dr. Hahn highlighted several key points in the new guidelines:

  • All patients with clinical evidence of active LN should have a renal biopsy unless it is strongly contraindicated.
  • Background therapies should be used in all patients with LN: hydroxychloroquine (HCQ); angiotensin inhibitors or angiotensin receptor blockers for patients with proteinuria greater than or equal to 0.5 g per 24 hours; and statin therapy for patients with LDL cholesterol higher than 100 mg/dL.
  • Women contemplating pregnancy should receive counseling from their physicians about risk.
  • Specific recommendations are given for dosing MMF in patients of different races.
  • African Americans and Latinos are not as likely to respond to cyclophosphamide (CYC) as well as other races do, so MMF may be the first choice for therapy.
  • Two different regimens of intravenous (IV) CYC therapy are recommended: low-dose “Euro-Lupus” CYC (500 mg IV once every two weeks for a total of six doses), followed by maintenance therapy with daily oral azathioprine or daily oral MMF; and high-dose CYC (500–1,000 mg/m2 IV once a month for six doses), followed by maintenance treatment with MMF or azathioprine. If CYC is being considered for treatment, the “Euro-Lupus” dose is recommended for white patients with Western European or Southern European racial/ethnic backgrounds.
  • Recommendations are given for starting doses for glucocorticoids and the situations where pulse therapy is recommended.
  • Guidance is provided for switching therapies in patients who do not respond to induction therapy, including the use of rituximab in some cases.
  • Either azathioprine or MMF can be used as maintenance therapy for patients who have responded to initiation therapy.

The recommended therapies for patients with LN with cellular crescents or membranous LN may be surprising to some physicians, Dr. Hahn says. For patients with cellular crescents, the new guidelines recommend either CYC or MMF for induction therapy, along with IV pulses of high-dose glucocorticoids and initiation of oral glucocorticoids at the higher range dose. Patients with membranous LN can be started on prednisone plus MMF.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

These guidelines are “more mycophenolate heavy than some of the textbooks, and less cyclophosphamide centric than earlier recommendations,” says Dr. Hahn, noting that neither drug has been approved by the Food and Drug Administration for treatment of LN. However, she believes the guidelines may go a long way in persuading reluctant payers to cover these drugs for patients with LN.

Also, the guidelines are “careful to say that nothing is contraindicated, because a physician providing direct care is in the best position to decide what therapies should be initiated, modified, or discontinued,” Dr. Hahn says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment of RA

The 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis recommends that targeting low disease activity or remission should be the goal of treatment for every patient with established RA or early RA, according to Dr. Singh.4

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesFrom the CollegeRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:AC&RAmerican College of Rheumatology (ACR)BiologicsdrugGlucocorticoidsGuidelinesLupusLupus nephritispatient careRheumatoid arthritisSystemic lupus erythematosustocilizumab

Related Articles

    Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support

    July 1, 2014

    Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus

    Combining Humanities, Clinical Care Essential to Providing Quality Healthcare

    February 15, 2017

    WASHINGTON, D.C.—Paulette Hahn, MD, associate professor of medicine specializing in rheumatology at the University of Florida (UF), said she once treated a patient named Monica, a UF undergraduate who had severe inflammatory muscle disease and severe lung disease. The patient’s disease was under control for the time being, but Monica knew she could take a…

    Lupus Nephritis Guidelines in Progress

    April 13, 2011

    A preview of the upcoming recommendations

    Trailblazers in Rheumatology

    July 26, 2023

    We were sad to learn that Rodanthi C. Kitridou, MD, MACR, passed away July 6, 2023, after a long illness. Dr. Kitridou was the longtime director of clinical rheumatology at at LAC/USC Medical Center in Los Angeles.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences